A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
July 27, 2018
End Date
July 15, 2023
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
July 27, 2018
End Date
July 15, 2023